These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11802628)

  • 1. Antiretroviral rounds. A very discordant response.
    Henry K; Jenny-Avital E
    AIDS Clin Care; 2002 Jan; 14(1):4-5, 8. PubMed ID: 11802628
    [No Abstract]   [Full Text] [Related]  

  • 2. Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
    Feinberg J
    AIDS Clin Care; 2006 Nov; 18(11):99. PubMed ID: 17183745
    [No Abstract]   [Full Text] [Related]  

  • 3. An open-label trial of stavudine, lamivudine and efavirenz in the treatment of HIV-positive, treatment-naive patients, and implications for clinical practice.
    Elion R; Green L; Cohen C; Green S; Baird I; Schrader S; Ward D
    Antivir Ther; 1999; 4 Suppl 3():89-91. PubMed ID: 16021878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral rounds. When success is a pain.
    Bartlett JG; del Rio C
    AIDS Clin Care; 2001 Aug; 13(8):74-5. PubMed ID: 11547461
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical trials group: two studies are now open to patients who qualify.
    Craig K
    HIV Clin; 2000; 12(1):5. PubMed ID: 11810862
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-HIV agents. Abacavir--as good as AZT?
    TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.
    Wasmuth JC; Herhaus C; Römer K; Salzberger B; Kaiser R; Schliefer K; Voigt E; Rockstroh JK
    AIDS; 2002 May; 16(7):1077-8. PubMed ID: 11953478
    [No Abstract]   [Full Text] [Related]  

  • 8. AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
    Gallant JE
    Hopkins HIV Rep; 2003 Jul; 15(4):1-2. PubMed ID: 14696559
    [No Abstract]   [Full Text] [Related]  

  • 9. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-nucleoside regimens versus efavirenz.
    De Luca A; Di Giambenedetto S
    N Engl J Med; 2004 Aug; 351(7):717-9; author reply 717-9. PubMed ID: 15306677
    [No Abstract]   [Full Text] [Related]  

  • 11. Triple nuke therapy--results after one year.
    TreatmentUpdate; 2001; 12(10):3-4. PubMed ID: 11570063
    [No Abstract]   [Full Text] [Related]  

  • 12. Options when HIV treatments fail.
    Treat Rev; 1998; (No 28):7-9. PubMed ID: 11365426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained responses to dual nucleoside therapy in women.
    Tashima KT; Fiore TC
    J Acquir Immune Defic Syndr; 2000 Dec; 25(4):371-2. PubMed ID: 11114839
    [No Abstract]   [Full Text] [Related]  

  • 14. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules.
    Portsmouth SD; Osorio J; McCormick K; Gazzard BG; Moyle GJ
    HIV Med; 2005 May; 6(3):185-90. PubMed ID: 15876285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New expanded access drugs for use in combination therapy.
    Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
    Landay AL; Bettendorf D; Chan E; Spritzler J; Schmitz JL; Bucy RP; Gonzalez CJ; Schnizlein-Bick CT; Evans T; Squires KE; Phair JP
    AIDS Res Hum Retroviruses; 2002 Jan; 18(2):95-102. PubMed ID: 11839142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
    Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
    [No Abstract]   [Full Text] [Related]  

  • 18. Top stories of 2004. ACTG 5095: efavirenz beats AZT + 3TC + abacavir.
    del Rio C
    AIDS Clin Care; 2005 Jan; 17(1):4. PubMed ID: 15717367
    [No Abstract]   [Full Text] [Related]  

  • 19. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
    Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B
    Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Valuable combination partner. Great benefit for therapy naive patients].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.